FDA Gives Priority Review to Lynparza as First-line Maintenance Therapy for Advanced Ovarian Cancer
News
The U.S. Food and Drug Administration (FDA) has agreed to review the use of Lynparza (olaparib) tablets as a maintenance treatment for women newly diagnosed with advanced ovarian cancer, Merck announced ... Read more